From a clinical and therapeutic potential point of view, another important finding from Troia et al. relies in the observation that elastin deficiency-induced hypertension could be pharmacologically reversed by chronic—not acute—treatment of Eln+/− mice with a NOX1 and 2 inhibitor, apocynin. This evidence concerns the gene NOX1 and hypertensive disorder.